<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-title>Cardiovascular Diabetology</journal-title><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1475-2840-7-5</article-id><article-id pub-id-type="pmid">18339204</article-id><article-id pub-id-type="doi">10.1186/1475-2840-7-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Association between the <italic>FTO </italic>rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Al-Attar</surname><given-names>Salam A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>salattar@robarts.ca</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Pollex</surname><given-names>Rebecca L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>rpollex@robarts.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Ban</surname><given-names>Matthew R</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mban@robarts.ca</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Young</surname><given-names>T Kue</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>kue.young@utoronto.ca</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Bjerregaard</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>pb@si-folkesundhed.dk</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Anand</surname><given-names>Sonia S</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>anands@mcmaster.ca</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Yusuf</surname><given-names>Salim</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>yusufs@mcmaster.ca</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Zinman</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>zinman@mshri.on.ca</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Harris</surname><given-names>Stewart B</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>sharris1@uwo.ca</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Hanley</surname><given-names>Anthony JG</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I7">7</xref><email>anthony.hanley@utoronto.ca</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Connelly</surname><given-names>Philip W</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>connellyp@smh.toronto.on.ca</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Huff</surname><given-names>Murray W</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I9">9</xref><email>mhuff@uwo.ca</email></contrib><contrib id="A13" corresp="yes" contrib-type="author"><name><surname>Hegele</surname><given-names>Robert A</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I9">9</xref><email>hegele@robarts.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Vascular Biology Research Group, Robarts Research Institute, London, Ontario, Canada</aff><aff id="I2"><label>2</label>Department of Public Health Sciences, University of Toronto, Ontario, Canada</aff><aff id="I3"><label>3</label>National Institute of Public Health, Copenhagen, Denmark</aff><aff id="I4"><label>4</label>Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada</aff><aff id="I5"><label>5</label>Department of Medicine, University of Toronto, and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada</aff><aff id="I6"><label>6</label>Thames Valley Family Practice Research Unit, University of Western Ontario, London, Ontario, Canada</aff><aff id="I7"><label>7</label>Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada</aff><aff id="I8"><label>8</label>Department of Laboratory Medicine and Pathobiology, University of Toronto, and the Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada</aff><aff id="I9"><label>9</label>Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>13</day><month>3</month><year>2008</year></pub-date><volume>7</volume><fpage>5</fpage><lpage>5</lpage><ext-link ext-link-type="uri" xlink:href="http://www.cardiab.com/content/7/1/5"/><history><date date-type="received"><day>24</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Al-Attar et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Al-Attar et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Al-Attar A Salam salattar@robarts.ca </dc:author><dc:title> Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Cardiovascular Diabetology 7(1): 5-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1475-2840(2008)7:1&#x0003c;5&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1475-2840</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The rs9939609 T&#x0003e;A single-nucleotide polymorphism (SNP) in the <italic>FTO </italic>gene has previously been found to be associated with obesity in European Caucasian samples. The objective of this study is to examine whether this association extends to metabolic syndrome (MetS) and applies in non-Caucasian samples.</p></sec><sec sec-type="methods"><title>Methods</title><p>The <italic>FTO </italic>rs9939609 SNP was genotyped in 2121 subjects from four different non-Caucasian geographical ancestries. Subjects were classified for the presence or absence of MetS according to the International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III definitions.</p></sec><sec><title>Results</title><p>Carriers of &#x02265; 1 copy of the rs9939609 A allele were significantly more likely to have IDF-defined MetS (35.8%) than non-carriers (31.2%), corresponding to a carrier odds ratio (OR) of 1.23 (95% confidence interval [CI] 1.01 to 1.50), with a similar trend for the NCEP ATP III-defined MetS. Subgroup analysis showed that the association was particularly strong in men. The association was related to a higher proportion of rs9939609 A allele carriers meeting the waist circumference criterion; a higher proportion also met the HDL cholesterol criterion compared with wild-type homozygotes.</p></sec><sec><title>Conclusion</title><p>Thus, the <italic>FTO </italic>rs9939609 SNP was associated with an increased risk for MetS in this multi-ethnic sample, confirming that the association extends to non-Caucasian population samples.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The metabolic syndrome (MetS) is a clinical entity characterized by abdominal obesity, hypertension, hypertriglyceridemia, depressed plasma high-density lipoprotein (HDL) cholesterol and elevated glucose [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. MetS is common, and will likely become even more pervasive, considering the poor lifestyle habits prevalent in many societies today. While the increased prevalence of MetS is primarily related to an imbalance between caloric intake and expenditure, genetic factors are also likely to be important. Each defining component has been previously associated with genetic factors, suggesting that genetic factors might underlie the overall MetS both independently and through more complex interactions [<xref ref-type="bibr" rid="B3">3</xref>]. While the precise definition of MetS is controversial, there is no question that the MetS concept has proven to be valuable clinically [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>A potential candidate underlying genetic susceptibility to MetS is the <italic>FTO </italic>(fat mass and obesity associated) gene, encoding the human analogue of <italic>fused toes </italic>in mice. The <italic>FTO </italic>gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase that is present in many tissues, but most abundant in the hypothalamus, the control center of energy balance [<xref ref-type="bibr" rid="B6">6</xref>]. Studies in mice showing that <italic>Fto </italic>mRNA levels are regulated by feeding and fasting have provided a mechanistic link between <italic>FTO </italic>and body weight and energy homeostasis [<xref ref-type="bibr" rid="B6">6</xref>]. Human population genetic studies have found <italic>FTO </italic>single nucleotide polymorphisms (SNPs) to be associated with type 2 diabetes [<xref ref-type="bibr" rid="B7">7</xref>] and obesity [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. The <italic>FTO </italic>rs9939609 SNP is of particular interest since it was found to be associated with obesity through independent studies of large Caucasian populations [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Since obesity is one of the key features of MetS, we wondered whether this association signal could be found with the complex trait of MetS and whether the association could be detected across other non-Caucasian populations. Thus, the purpose of this study was to examine the <italic>FTO </italic>rs9939609 SNP as a potential genetic candidate for MetS, defined by both the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and the International Diabetes Federation (IDF) criteria, in a sample derived from multiple non-Caucasian geographic ancestries.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study subjects</title><p>The multi-ethnic study included Canadians of South Asian and Chinese descent, Oji-Cree (Ontario, Canada), and Inuit from Greenland. All subjects for the current study were collected from one of the following population studies: 1) the Study of Health Assessment and Risk in Ethnic Groups [<xref ref-type="bibr" rid="B12">12</xref>]; 2) the Sandy Lake Health and Diabetes Project [<xref ref-type="bibr" rid="B13">13</xref>]; and 3) the Greenland Population Study [<xref ref-type="bibr" rid="B14">14</xref>]. The details of these studies have been described previously [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Signed informed consent was obtained from all participants and the study was approved by the University of Western Ontario Ethics Review Board (protocol #7920E). For the current analysis, the number of subjects &#x02265; 18 years of age with both sufficient DNA for <italic>FTO </italic>genotype determination and a complete set of data for MetS diagnosis included 325 South Asians, 299 Chinese, 400 Oji-Cree, and 1097 Greenland Inuit; a total of 2121 subjects (53.9% female). There was no exclusion based on diabetes status.</p></sec><sec><title>Physical measurements</title><p>Measurements of waist circumference, blood pressure, fasting analytes, including venous plasma glucose, serum cholesterol, triglycerides (TG), low-density lipoprotein (LDL) cholesterol, and HDL cholesterol were performed as described [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>].</p></sec><sec><title>Metabolic syndrome classification</title><p>According to the NCEP ATP III criteria [<xref ref-type="bibr" rid="B1">1</xref>], MetS was identified if a subject had &#x02265; 3 of: 1) increased waist circumference (&#x0003e;102 cm [&#x0003e;40 inches] for men, &#x0003e;88 cm [&#x0003e;35 inches] for women); 2) elevated plasma TG (&#x02265; 1.69 mmol/L [&#x02265; 150 mg/dL]); 3) low plasma HDL cholesterol (&#x0003c;1.04 mmol/L [&#x0003c;40 mg/dL] for men, &#x0003c;1.29 mmol/L [&#x0003c;50 mg/dL] for women); 4) hypertension (&#x02265; 130/&#x02265; 85 mmHg) or current medication; or 5) impaired fasting glucose (&#x02265; 6.1 mmol/L [&#x02265; 110 mg/dL]).</p><p>The IDF criteria [<xref ref-type="bibr" rid="B15">15</xref>] identifies MetS for subjects with central obesity, according to ethnic specific guidelines (waist circumference for South Asians and Chinese &#x02265; 90 cm for men, &#x02265; 80 cm for women), plus any two of: 1) elevated plasma TG (&#x02265; 1.69 mmol/L [&#x02265; 150 mg/dL]); 2) low plasma HDL cholesterol (&#x0003c;1.04 mmol/L [&#x0003c;40 mg/dL] for men, &#x0003c;1.29 mmol/L [&#x0003c;50 mg/dL] for women); 3) hypertension (&#x02265; 130/&#x02265; 85 mmHg) or current medication; or 4) impaired fasting glucose (&#x02265; 5.6 mmol/L [&#x02265; 100 mg/dL]) or previously diagnosed type 2 diabetes. Since no quantitative thresholds exist yet for aboriginal populations, these subjects were also evaluated using the South Asian and Chinese threshold values for waist circumference.</p></sec><sec><title>Genotyping of the FTO polymorphism</title><p>Detection of the <italic>FTO </italic>SNP rs9939609 was carried out using a validated TaqMan genotyping assay (Assay ID C_25638153_10; Applied Biosystems, Foster City, CA). SNP genotyping was performed using an allelic discrimination assay (TaqMan<sup>&#x000ae; </sup>SNP Genotyping Assays, Applied Biosystems, Foster City, CA) using the 7900HT Fast Real-Time PCR System and genotypes were read using automated software (SDS 2.3, Applied Biosystems, Foster City, CA). Reactions were run in 5 &#x003bc;L volumes using an amplification protocol of 95&#x000b0;C for 10 minutes, followed by 50 cycles of 95&#x000b0;C for 15 seconds, then 60&#x000b0;C for 1.5 minutes.</p></sec><sec><title>Statistical analysis</title><p>SAS version 9.1 (SAS Institute, Cary, NC) was used for all statistical comparisons. Data are presented as means &#x000b1; standard deviation (SD) or as percentages for discrete variables. Between-group differences in discrete variables were analyzed using &#x003c7;<sup>2 </sup>analysis and odds ratios (OR) were calculated using the "case-control" method in the FREQ procedure in SAS. Differences in quantitative traits were analyzed by ANOVA, using the general linear model, adjusted for age. The significance of deviations of observed genotype frequencies from those predicted by the Hardy-Weinberg equation were evaluated with &#x003c7;<sup>2 </sup>tests. The rs9939609 T&#x0003e;A genotypes were included in the analysis as a dichotomous variable, in both dominant and recessive models. Statistical significance was taken at a P-value&#x0003c;0.05 for all comparisons.</p></sec></sec><sec><title>Results</title><p>Table <xref ref-type="table" rid="T1">1</xref> shows the demographic and metabolic characteristics of the populations included in the study. The <italic>FTO </italic>rs9939609 A allele frequencies were 0.32, 0.12, 0.066, and 0.18, for the South Asians, Chinese, Oji-Cree, and Greenland Inuit, respectively. The genotype frequencies did not deviate from the Hardy-Weinberg predictions (data not shown).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical and biochemical data of subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Male</bold></td><td align="center"><bold>Female</bold></td><td align="center"><bold><italic>P</italic>-value</bold></td></tr><tr><td></td><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Greenland Inuit</bold></td><td align="center"><bold>n = 486</bold></td><td align="center"><bold>n = 622</bold></td><td></td></tr></thead><tbody><tr><td align="left">age (years)</td><td align="center">46.2 &#x000b1; 12.9</td><td align="center">45.8 &#x000b1; 13.1</td><td align="center">NS (0.60)</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="center">26.2 &#x000b1; 4.6</td><td align="center">26.7 &#x000b1; 5.4<sup>2</sup></td><td align="center">NS (0.072)</td></tr><tr><td align="left">waist (cm)</td><td align="center">91.1 &#x000b1; 12.2</td><td align="center">88.1 &#x000b1; 13.5</td><td align="center">0.0001</td></tr><tr><td align="left">systolic BP (mmHg)</td><td align="center">120 &#x000b1; 17</td><td align="center">119 &#x000b1; 20</td><td align="center">NS (0.14)</td></tr><tr><td align="left">diastolic BP (mmHg)</td><td align="center">74 &#x000b1; 11</td><td align="center">72 &#x000b1; 11</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">total cholesterol (mmol/L)</td><td align="center">5.99 &#x000b1; 1.18</td><td align="center">6.02 &#x000b1; 1.13</td><td align="center">NS (0.77)</td></tr><tr><td align="left">triglycerides (mmol/L)</td><td align="center">1.15 &#x000b1; 0.66</td><td align="center">1.12 &#x000b1; 0.61</td><td align="center">NS (0.090)</td></tr><tr><td align="left">LDL cholesterol (mmol/L)</td><td align="center">3.90 &#x000b1; 1.09<sup>1</sup></td><td align="center">3.89 &#x000b1; 1.06<sup>2</sup></td><td align="center">NS (0.67)</td></tr><tr><td align="left">HDL cholesterol (mmol/L)</td><td align="center">1.56 &#x000b1; 0.49</td><td align="center">1.62 &#x000b1; 0.42</td><td align="center">0.0015</td></tr><tr><td align="left">fasting glucose (mmol/L)</td><td align="center">5.83 &#x000b1; 0.89</td><td align="center">5.76 &#x000b1; 1.34</td><td align="center">NS (0.21)</td></tr><tr><td align="left">MetS (%)</td><td align="center">12.1</td><td align="center">17.0</td><td align="center">0.017</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>Oji-Cree</bold></td><td align="center"><bold>n = 218</bold></td><td align="center"><bold>n = 291</bold></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">age (years)</td><td align="center">35.9 &#x000b1; 14.5</td><td align="center">35.7 &#x000b1; 14.7</td><td align="center">NS (0.85)</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="center">26.8 &#x000b1; 4.6</td><td align="center">29.1 &#x000b1; 5.5</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">waist (cm)</td><td align="center">96.9 &#x000b1; 12.2</td><td align="center">95.0 &#x000b1; 11.9</td><td align="center">NS (0.073)</td></tr><tr><td align="left">systolic BP (mmHg)</td><td align="center">122 &#x000b1; 14</td><td align="center">118 &#x000b1; 16</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">diastolic BP (mmHg)</td><td align="center">70 &#x000b1; 12</td><td align="center">67 &#x000b1; 10</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">total cholesterol (mmol/L)</td><td align="center">4.83 &#x000b1; 0.98</td><td align="center">4.59 &#x000b1; 0.82</td><td align="center">0.0001</td></tr><tr><td align="left">triglycerides (mmol/L)</td><td align="center">1.63 &#x000b1; 0.85</td><td align="center">1.51 &#x000b1; 0.71</td><td align="center">0.0003</td></tr><tr><td align="left">LDL cholesterol (mmol/L)</td><td align="center">2.91 &#x000b1; 0.82<sup>3</sup></td><td align="center">2.62 &#x000b1; 0.65<sup>4</sup></td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">HDL cholesterol (mmol/L)</td><td align="center">1.19 &#x000b1; 0.30</td><td align="center">1.28 &#x000b1; 0.28</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">fasting glucose (mmol/L)</td><td align="center">6.73 &#x000b1; 3.25</td><td align="center">6.77 &#x000b1; 3.50</td><td align="center">NS (0.61)</td></tr><tr><td align="left">MetS (%)</td><td align="center">30.3</td><td align="center">39.2</td><td align="center">0.028</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>South Asian</bold></td><td align="center"><bold>n = 180</bold></td><td align="center"><bold>n = 147</bold></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">age (years)</td><td align="center">49.9 &#x000b1; 8.9</td><td align="center">49.0 &#x000b1; 9.6</td><td align="center">NS (0.37)</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="center">26.1 &#x000b1; 4.3<sup>5</sup></td><td align="center">26.5 &#x000b1; 3.8</td><td align="center">NS (0.37)</td></tr><tr><td align="left">waist (cm)</td><td align="center">94.7 &#x000b1; 9.7</td><td align="center">86.0 &#x000b1; 10.6</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">systolic BP (mmHg)</td><td align="center">121 &#x000b1; 16</td><td align="center">117 &#x000b1; 19</td><td align="center">0.034</td></tr><tr><td align="left">diastolic BP (mmHg)</td><td align="center">80 &#x000b1; 12</td><td align="center">71 &#x000b1; 10</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">total cholesterol (mmol/L)</td><td align="center">5.26 &#x000b1; 0.98</td><td align="center">5.15 &#x000b1; 0.94</td><td align="center">NS (0.41)</td></tr><tr><td align="left">triglycerides (mmol/L)</td><td align="center">2.05 &#x000b1; 1.31</td><td align="center">1.92 &#x000b1; 1.27</td><td align="center">NS (0.30)</td></tr><tr><td align="left">LDL cholesterol (mmol/L)</td><td align="center">3.45 &#x000b1; 0.84<sup>6</sup></td><td align="center">3.18 &#x000b1; 0.79<sup>7</sup></td><td align="center">0.0069</td></tr><tr><td align="left">HDL cholesterol (mmol/L)</td><td align="center">0.95 &#x000b1; 0.26</td><td align="center">1.13 &#x000b1; 0.32</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">fasting glucose (mmol/L)</td><td align="center">5.95 &#x000b1; 1.89</td><td align="center">5.49 &#x000b1; 1.58</td><td align="center">0.020</td></tr><tr><td align="left">MetS (%)</td><td align="center">31.1</td><td align="center">34.0</td><td align="center">NS (0.38)</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>Chinese</bold></td><td align="center"><bold>n = 148</bold></td><td align="center"><bold>n = 151</bold></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">age (years)</td><td align="center">48.8 &#x000b1; 9.3</td><td align="center">46.6 &#x000b1; 8.4</td><td align="center">0.030</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="center">25.2 &#x000b1; 3.4</td><td align="center">22.7 &#x000b1; 3.5</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">waist (cm)</td><td align="center">89.6 &#x000b1; 9.1</td><td align="center">75.2 &#x000b1; 7.9</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">systolic BP (mmHg)</td><td align="center">122 &#x000b1; 17</td><td align="center">112 &#x000b1; 20</td><td align="center">0.022</td></tr><tr><td align="left">diastolic BP (mmHg)</td><td align="center">80 &#x000b1; 10</td><td align="center">70 &#x000b1; 12</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">total cholesterol (mmol/L)</td><td align="center">5.29 &#x000b1; 1.00</td><td align="center">4.85 &#x000b1; 0.84</td><td align="center">0.0057</td></tr><tr><td align="left">triglycerides (mmol/L)</td><td align="center">2.14 &#x000b1; 1.61</td><td align="center">1.38 &#x000b1; 1.03</td><td align="center">0.0055</td></tr><tr><td align="left">LDL cholesterol (mmol/L)</td><td align="center">3.34 &#x000b1; 0.84<sup>8</sup></td><td align="center">2.90 &#x000b1; 0.71<sup>9</sup></td><td align="center">0.0006</td></tr><tr><td align="left">HDL cholesterol (mmol/L)</td><td align="center">1.03 &#x000b1; 0.29</td><td align="center">1.33 &#x000b1; 0.36</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">fasting glucose (mmol/L)</td><td align="center">5.44 &#x000b1; 1.29</td><td align="center">4.98 &#x000b1; 0.60</td><td align="center">0.016</td></tr><tr><td align="left">MetS (%)</td><td align="center">28.4</td><td align="center">10.6</td><td align="center">0.0003</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>n = 483, <sup>2</sup>n = 620, <sup>3</sup>n = 216, <sup>4</sup>n = 289, <sup>5</sup>n = 179, <sup>6</sup>n = 169, <sup>7</sup>n = 141, <sup>8</sup>n = 139, <sup>9</sup>n = 148</p><p>Abbreviations: BMI, body mass index; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; MetS, metabolic syndrome; NS, not significant.</p><p>Data are means &#x000b1; standard deviation (SD). <italic>P</italic>-values are adjusted for age; <italic>P</italic>-values for blood pressure, cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, and glucose are also adjusted for BMI.</p></table-wrap-foot></table-wrap><p>Analysis across the 4 study populations indicated that <italic>FTO </italic>rs9939609 A allele carriers had an increased risk of MetS, according to the IDF definition (carrier OR 1.23, 95% CI 1.01 to 1.50, <italic>P </italic>= 0.036) (Table <xref ref-type="table" rid="T2">2</xref>). Subgroup analysis of females showed that the carrier OR was 1.05 (95% CI 0.80 to 1.38, <italic>P </italic>= NS [0.74]). Subgroup analysis of males showed that the carrier OR was 1.46 (95% CI 1.10 to 1.94, <italic>P </italic>= 0.0081). By individual ethnic populations, a significant increased risk for MetS was observed for <italic>FTO </italic>rs9939609 A allele carriers only in the South Asian group (<italic>P </italic>= 0.027). Analysis of the NCEP ATP III definition for MetS showed a similar trend towards increased risk for <italic>FTO </italic>rs9939609 A allele carriers compared to TT homozygotes (carrier OR 1.26, 95% CI 1.02 to 1.57, <italic>P </italic>= 0.036) (Table <xref ref-type="table" rid="T2">2</xref>). A significant increased risk for NCEP ATP III MetS was observed for <italic>FTO </italic>rs9939609 A allele carriers among Greenland Inuit (<italic>P </italic>= 0.037).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Metabolic syndrome and metabolic syndrome component prevalence in subjects when classified in accordance to their genotype of the <italic>FTO </italic>rs9939609 T&#x0003e;A polymorphism</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>TT</bold></td><td align="center"><bold>AA &#x00026; AT</bold></td><td align="center"><bold>OR (95% CI)</bold></td><td align="center"><bold>P-value</bold></td></tr></thead><tbody><tr><td align="left">Overall N = 2121</td><td align="center">1482</td><td align="center">639</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">IDF MetS (%)</td><td align="center">31.2</td><td align="center">35.8</td><td align="center">1.23 (1.01, 1.50)</td><td align="center">0.036</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">&#x02003;South Asian</td><td align="center">36.8</td><td align="center">49.1</td><td align="center">1.66 (1.06, 2.58)</td><td align="center">0.027</td></tr><tr><td align="left">&#x02003;Chinese</td><td align="center">24.6</td><td align="center">22.4</td><td align="center">0.89 (0.46, 1.69)</td><td align="center">0.71</td></tr><tr><td align="left">&#x02003;Oji-Cree</td><td align="center">48.9</td><td align="center">51.9</td><td align="center">1.13 (0.63, 2.03)</td><td align="center">0.68</td></tr><tr><td align="left">&#x02003;Greenland Inuit</td><td align="center">23.9</td><td align="center">29.4</td><td align="center">1.33 (0.99, 1.77)</td><td align="center">0.051</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">NCEP ATP III MetS (%)</td><td align="center">21.1</td><td align="center">25.2</td><td align="center">1.26 (1.02, 1.57)</td><td align="center">0.036</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">&#x02003;South Asian</td><td align="center">28.3</td><td align="center">35.8</td><td align="center">1.42 (0.88, 2.27)</td><td align="center">0.15</td></tr><tr><td align="left">&#x02003;Chinese</td><td align="center">18.5</td><td align="center">22.4</td><td align="center">1.27 (0.65, 2.46)</td><td align="center">0.48</td></tr><tr><td align="left">&#x02003;Oji-Cree</td><td align="center">36.2</td><td align="center">40.4</td><td align="center">1.19 (0.66, 2.17)</td><td align="center">0.56</td></tr><tr><td align="left">&#x02003;Greenland Inuit</td><td align="center">13.3</td><td align="center">18.2</td><td align="center">1.44 (1.02, 2.04)</td><td align="center">0.037</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">MetS BP (%)</td><td align="center">30.3</td><td align="center">33.2</td><td align="center">1.14 (0.94, 1.39)</td><td align="center">0.19</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">&#x02003;South Asian</td><td align="center">35.5</td><td align="center">33.0</td><td align="center">0.89 (0.56, 1.41)</td><td align="center">0.62</td></tr><tr><td align="left">&#x02003;Chinese</td><td align="center">32.8</td><td align="center">40.3</td><td align="center">1.39 (0.79, 2.43)</td><td align="center">0.25</td></tr><tr><td align="left">&#x02003;Oji-Cree</td><td align="center">27.6</td><td align="center">19.2</td><td align="center">0.63 (0.30, 1.30)</td><td align="center">0.20</td></tr><tr><td align="left">&#x02003;Greenland Inuit</td><td align="center">29.7</td><td align="center">34.0</td><td align="center">1.22 (0.93, 1.60)</td><td align="center">0.16</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">MetS Triglycerides (%)</td><td align="center">25.0</td><td align="center">26.5</td><td align="center">1.08 (0.87, 1.34)</td><td align="center">0.47</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">&#x02003;South Asian</td><td align="center">46.1</td><td align="center">46.8</td><td align="center">1.03 (0.67, 1.60)</td><td align="center">0.89</td></tr><tr><td align="left">&#x02003;Chinese</td><td align="center">38.8</td><td align="center">31.3</td><td align="center">0.72 (0.40, 1.29)</td><td align="center">0.27</td></tr><tr><td align="left">&#x02003;Oji-Cree</td><td align="center">33.1</td><td align="center">40.4</td><td align="center">1.37 (0.76, 2.49)</td><td align="center">0.30</td></tr><tr><td align="left">&#x02003;Greenland Inuit</td><td align="center">12.7</td><td align="center">13.3</td><td align="center">1.05 (0.72, 1.54)</td><td align="center">0.79</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">MetS HDL (%)</td><td align="center">33.7</td><td align="center">39.6</td><td align="center">1.29 (1.07, 1.56)</td><td align="center">0.0089</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">&#x02003;South Asian</td><td align="center">69.1</td><td align="center">71.7</td><td align="center">1.13 (0.70, 1.83)</td><td align="center">0.61</td></tr><tr><td align="left">&#x02003;Chinese</td><td align="center">51.7</td><td align="center">61.2</td><td align="center">1.47 (0.85, 2.56)</td><td align="center">0.17</td></tr><tr><td align="left">&#x02003;Oji-Cree</td><td align="center">45.7</td><td align="center">59.6</td><td align="center">1.75 (0.97, 3.17)</td><td align="center">0.061</td></tr><tr><td align="left">&#x02003;Greenland Inuit</td><td align="center">15.3</td><td align="center">16.4</td><td align="center">1.09 (0.77, 1.53)</td><td align="center">0.64</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">MetS Glucose (%)</td><td align="center">45.3</td><td align="center">47.7</td><td align="center">1.10 (0.92, 1.33)</td><td align="center">0.30</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">&#x02003;South Asian</td><td align="center">25.7</td><td align="center">34.1</td><td align="center">1.50 (0.93, 2.43)</td><td align="center">0.098</td></tr><tr><td align="left">&#x02003;Chinese</td><td align="center">17.2</td><td align="center">20.9</td><td align="center">1.27 (0.64, 2.50)</td><td align="center">0.49</td></tr><tr><td align="left">&#x02003;Oji-Cree</td><td align="center">53.5</td><td align="center">44.2</td><td align="center">0.69 (0.38, 1.24)</td><td align="center">0.21</td></tr><tr><td align="left">&#x02003;Greenland Inuit</td><td align="center">54.1</td><td align="center">60.2</td><td align="center">1.28 (0.99, 1.66)</td><td align="center">0.059</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">MetS Waist (IDF) (%)</td><td align="center">60.9</td><td align="center">65.0</td><td align="center">1.19 (0.98, 1.44)</td><td align="center">0.080</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">&#x02003;South Asian</td><td align="center">64.5</td><td align="center">75.1</td><td align="center">1.67 (1.03, 2.69)</td><td align="center">0.036</td></tr><tr><td align="left">&#x02003;Chinese</td><td align="center">34.9</td><td align="center">32.8</td><td align="center">0.91 (0.51, 1.62)</td><td align="center">0.75</td></tr><tr><td align="left">&#x02003;Oji-Cree</td><td align="center">81.0</td><td align="center">78.9</td><td align="center">0.87 (0.43, 1.79)</td><td align="center">0.71</td></tr><tr><td align="left">&#x02003;Greenland Inuit</td><td align="center">58.9</td><td align="center">64.0</td><td align="center">1.24 (0.95, 1.61)</td><td align="center">0.11</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">BMI&#x0003e;33 kg/m<sup>2 </sup>(%)</td><td align="center">8.1</td><td align="center">10.6</td><td align="center">1.35 (0.99, 1.84)</td><td align="center">0.060</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">&#x02003;South Asian</td><td align="center">4.0</td><td align="center">5.8</td><td align="center">1.48 (0.53, 4.18)</td><td align="center">0.45</td></tr><tr><td align="left">&#x02003;Chinese</td><td align="center">2.2</td><td align="center">1.5</td><td align="center">0.69 (0.079, 5.99)</td><td align="center">0.73</td></tr><tr><td align="left">&#x02003;Oji-Cree</td><td align="center">13.5</td><td align="center">26.9</td><td align="center">2.36 (1.19, 4.68)</td><td align="center">0.012</td></tr><tr><td align="left">&#x02003;Greenland Inuit</td><td align="center">8.3</td><td align="center">12.4</td><td align="center">1.57 (1.04, 2.36)</td><td align="center">0.032</td></tr></tbody></table></table-wrap><p>No significant increased risk of MetS was observed overall for AA homozygotes, for either the IDF or NCEP ATP III definitions, upon repeating the analyses using a recessive model for the <italic>FTO </italic>rs9939609 A allele. The non-significant trends suggested that sample numbers were insufficient for detecting an association with this particular trait.</p><p>Analysis of the entire sample revealed no significant increase in blood pressure, plasma triglycerides or glucose levels (Table <xref ref-type="table" rid="T2">2</xref>). However, meta-analysis indicated that significantly more <italic>FTO </italic>rs9939609 A allele carriers met the MetS criteria for depressed HDL cholesterol (<italic>P </italic>= 0.0089), and there was a nonsignificant trend towards increased waist circumference and increased BMI for <italic>FTO </italic>rs9939609 A allele carriers (<italic>P </italic>= 0.080 and 0.060, respectively) (Table <xref ref-type="table" rid="T2">2</xref>).</p></sec><sec><title>Discussion</title><p>Our study of <italic>FTO </italic>as a candidate gene for MetS in a sample from multiple non-Caucasian geographical ancestries showed 1) significant association with the <italic>FTO </italic>gene, with rs9939609 A allele carriers, particularly males, having an increased risk of MetS (carrier OR 1.23, 95% CI 1.01 to 1.50; <italic>P </italic>= 0.036) (Table <xref ref-type="table" rid="T2">2</xref>); and <xref ref-type="table" rid="T2">2</xref>) this association was related to higher proportion of subjects with depressed HDL cholesterol and a trend towards increased waist circumference. Similar trends were observed for the NCEP ATP III definition of MetS.</p><p>This is the first report of an association between the <italic>FTO </italic>rs9939609 A allele and MetS. Furthermore, it extends the association of this allele beyond Caucasian samples. Although the observation may help understand the molecular etiology of MetS, this association requires replication in larger studies, considering the possibility of a spurious association due to population stratification or another such limitation [<xref ref-type="bibr" rid="B16">16</xref>]. Despite considerations regarding sample size however, the results reaffirm the established association between the <italic>FTO </italic>rs9939609 A allele with obesity in past findings [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. However, MetS is a complex disorder, and only a few of the previously associated genes, such as <italic>APOC3 </italic>and <italic>PPARG</italic>, have been replicated in more than one study sample [<xref ref-type="bibr" rid="B4">4</xref>]. Aside from the need to replicate the <italic>FTO </italic>association in other larger study samples, the mechanism underlying the association also needs to be investigated. The mechanism underlying the association may be related to: 1) a direct function of <italic>FTO </italic>[<xref ref-type="bibr" rid="B6">6</xref>] or 2) linkage disequilibrium of the tested variant with another causative change in a gene near the <italic>FTO </italic>locus.</p><p>Analysis of the overall sample indicated that significantly more <italic>FTO </italic>rs9939609 A allele carriers met the MetS criteria for depressed HDL cholesterol (<italic>P </italic>= 0.0089) than non-carriers. In addition, values were close to significance also for increased waist circumference (<italic>P </italic>= 0.080) and increased BMI (<italic>P </italic>= 0.060) among A allele carriers (Table <xref ref-type="table" rid="T2">2</xref>). This indicates that the association of the <italic>FTO </italic>rs9939609 A allele with the MetS was related in part to both the obesity component, but also the HDL component, suggesting that this genetic marker may have a broader relationship with individual components of this complex trait.</p><p>Although the meta-analysis across the four non-Caucasian study populations showed an association between MetS and the common rs9939609 SNP in <italic>FTO</italic>, analyses by individual ethnic populations indicated a significant increased risk for MetS only among the South Asians (IDF definition) and Greenland Inuit (NCEP ATP III definition). Thus, the overall association is primarily due to these two populations, with little influence from the Chinese and Oji-Cree. Again, replication of the <italic>FTO </italic>association in other larger study samples is essential for clarification. Further evidence against an association for the Chinese can be found in a recent study of 3,210 unrelated Chinese Han subjects from Shanghai and Beijing where no association found between the rs9939609 SNP and obesity [<xref ref-type="bibr" rid="B17">17</xref>].</p><p>In summary, we report an association between MetS and the common rs9939609 SNP in <italic>FTO</italic>. The observed consistent association between MetS and <italic>FTO </italic>in a non-Caucasian multi-ethnic study group, including populations which differ considerably in MetS prevalence, strengthens the likelihood that the <italic>FTO </italic>locus is related to obesity and MetS. Future replication of this association in larger sized samples and devising functional molecular studies will further enhance the validity of association and the causative relationship between the <italic>FTO </italic>variant and MetS.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SAA and RLP participated in the experimental design, data acquisition and analysis, interpretation of results, and manuscript writing. MRB participated in the analysis of the data. TKY, PB, SSA, SY, BZ, SBH, AJGH, PWC, and MWH were involved in the provision of patient samples and/or clinical data. RAH participated in the experimental design, data analysis and interpretation of results and manuscript writing. All authors approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>RAH is supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics, a Career Investigator award from the Heart and Stroke Foundation of Ontario (CI-5710), and operating grants from the Canadian Institutes for Health Research (MOP-13430, MOP-39533, MOP-39833), the Heart and Stroke Foundation of Ontario (PRG-5967, NA-6059, T-6018), the Ontario Research Fund and by Genome Canada through the Ontario Genomics Institute. SAA is the recipient of the Master's Studentship Award from the Heart and Stroke Foundation of Ontario.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><article-title>Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>2486</fpage><lpage>2497</lpage><pub-id pub-id-type="pmid">11368702</pub-id><pub-id pub-id-type="doi">10.1001/jama.285.19.2486</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eckel</surname><given-names>RH</given-names></name><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><article-title>The metabolic syndrome</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>1415</fpage><lpage>1428</lpage><pub-id pub-id-type="pmid">15836891</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)66378-7</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groop</surname><given-names>L</given-names></name></person-group><article-title>Genetics of the metabolic syndrome</article-title><source>Br J Nutr</source><year>2000</year><volume>83 Suppl 1</volume><fpage>S39</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">10889791</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pollex</surname><given-names>RL</given-names></name><name><surname>Hegele</surname><given-names>RA</given-names></name></person-group><article-title>Genetic determinants of the metabolic syndrome</article-title><source>Nat Clin Pract Cardiovasc Med</source><year>2006</year><volume>3</volume><fpage>482</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">16932765</pub-id><pub-id pub-id-type="doi">10.1038/ncpcardio0638</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>G</given-names></name><name><surname>Hegele</surname><given-names>RA</given-names></name></person-group><article-title>Genetic forms of the cardiometabolic syndrome: What can they tell the clinician?</article-title><source>JCMS</source><year>2007</year><volume>2</volume><fpage>45</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">17684446</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerken</surname><given-names>T</given-names></name><name><surname>Girard</surname><given-names>CA</given-names></name><name><surname>Tung</surname><given-names>YC</given-names></name><name><surname>Webby</surname><given-names>CJ</given-names></name><name><surname>Saudek</surname><given-names>V</given-names></name><name><surname>Hewitson</surname><given-names>KS</given-names></name><name><surname>Yeo</surname><given-names>GS</given-names></name><name><surname>McDonough</surname><given-names>MA</given-names></name><name><surname>Cunliffe</surname><given-names>S</given-names></name><name><surname>McNeill</surname><given-names>LA</given-names></name><name><surname>Galvanovskis</surname><given-names>J</given-names></name><name><surname>Rorsman</surname><given-names>P</given-names></name><name><surname>Robins</surname><given-names>P</given-names></name><name><surname>Prieur</surname><given-names>X</given-names></name><name><surname>Coll</surname><given-names>AP</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Jovanovic</surname><given-names>Z</given-names></name><name><surname>Farooqi</surname><given-names>IS</given-names></name><name><surname>Sedgwick</surname><given-names>B</given-names></name><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Lindahl</surname><given-names>T</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Ashcroft</surname><given-names>FM</given-names></name><name><surname>O'Rahilly</surname><given-names>S</given-names></name><name><surname>Schofield</surname><given-names>CJ</given-names></name></person-group><article-title>The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase</article-title><source>Science</source><year>2007</year><volume>318</volume><fpage>1469</fpage><lpage>1472</lpage><pub-id pub-id-type="pmid">17991826</pub-id><pub-id pub-id-type="doi">10.1126/science.1151710</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horikoshi</surname><given-names>M</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>C</given-names></name><name><surname>Shojima</surname><given-names>N</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name><name><surname>Ueki</surname><given-names>K</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name></person-group><article-title>Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population</article-title><source>Diabetologia</source><year>2007</year><volume>50</volume><fpage>2461</fpage><lpage>2466</lpage><pub-id pub-id-type="pmid">17928989</pub-id><pub-id pub-id-type="doi">10.1007/s00125-007-0827-5</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><article-title>Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>661</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">17554300</pub-id><pub-id pub-id-type="doi">10.1038/nature05911</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frayling</surname><given-names>TM</given-names></name><name><surname>Timpson</surname><given-names>NJ</given-names></name><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>Zeggini</surname><given-names>E</given-names></name><name><surname>Freathy</surname><given-names>RM</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Perry</surname><given-names>JR</given-names></name><name><surname>Elliott</surname><given-names>KS</given-names></name><name><surname>Lango</surname><given-names>H</given-names></name><name><surname>Rayner</surname><given-names>NW</given-names></name><name><surname>Shields</surname><given-names>B</given-names></name><name><surname>Harries</surname><given-names>LW</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Groves</surname><given-names>CJ</given-names></name><name><surname>Knight</surname><given-names>B</given-names></name><name><surname>Patch</surname><given-names>AM</given-names></name><name><surname>Ness</surname><given-names>AR</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name><name><surname>Ring</surname><given-names>SM</given-names></name><name><surname>Ben-Shlomo</surname><given-names>Y</given-names></name><name><surname>Jarvelin</surname><given-names>MR</given-names></name><name><surname>Sovio</surname><given-names>U</given-names></name><name><surname>Bennett</surname><given-names>AJ</given-names></name><name><surname>Melzer</surname><given-names>D</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Loos</surname><given-names>RJ</given-names></name><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Karpe</surname><given-names>F</given-names></name><name><surname>Owen</surname><given-names>KR</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Hitman</surname><given-names>GA</given-names></name><name><surname>Palmer</surname><given-names>CN</given-names></name><name><surname>Doney</surname><given-names>AS</given-names></name><name><surname>Morris</surname><given-names>AD</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name></person-group><article-title>A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>889</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">17434869</pub-id><pub-id pub-id-type="doi">10.1126/science.1141634</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groop</surname><given-names>L</given-names></name></person-group><article-title>From fused toes in mice to human obesity</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>706</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">17534362</pub-id><pub-id pub-id-type="doi">10.1038/ng0607-706</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Bonnycastle</surname><given-names>LL</given-names></name><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Duren</surname><given-names>WL</given-names></name><name><surname>Erdos</surname><given-names>MR</given-names></name><name><surname>Stringham</surname><given-names>HM</given-names></name><name><surname>Chines</surname><given-names>PS</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><name><surname>Prokunina-Olsson</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>CJ</given-names></name><name><surname>Swift</surname><given-names>AJ</given-names></name><name><surname>Narisu</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Pruim</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Conneely</surname><given-names>KN</given-names></name><name><surname>Riebow</surname><given-names>NL</given-names></name><name><surname>Sprau</surname><given-names>AG</given-names></name><name><surname>Tong</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>PP</given-names></name><name><surname>Hetrick</surname><given-names>KN</given-names></name><name><surname>Barnhart</surname><given-names>MW</given-names></name><name><surname>Bark</surname><given-names>CW</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Watkins</surname><given-names>L</given-names></name><name><surname>Xiang</surname><given-names>F</given-names></name><name><surname>Saramies</surname><given-names>J</given-names></name><name><surname>Buchanan</surname><given-names>TA</given-names></name><name><surname>Watanabe</surname><given-names>RM</given-names></name><name><surname>Valle</surname><given-names>TT</given-names></name><name><surname>Kinnunen</surname><given-names>L</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Pugh</surname><given-names>EW</given-names></name><name><surname>Doheny</surname><given-names>KF</given-names></name><name><surname>Bergman</surname><given-names>RN</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name></person-group><article-title>A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>1341</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">17463248</pub-id><pub-id pub-id-type="doi">10.1126/science.1142382</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>SS</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Vuksan</surname><given-names>V</given-names></name><name><surname>Devanesen</surname><given-names>S</given-names></name><name><surname>Montague</surname><given-names>P</given-names></name><name><surname>Kelemen</surname><given-names>L</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><name><surname>Sigouin</surname><given-names>C</given-names></name><name><surname>Teo</surname><given-names>KK</given-names></name><name><surname>Lonn</surname><given-names>E</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Hegele</surname><given-names>RA</given-names></name><name><surname>McQueen</surname><given-names>M</given-names></name></person-group><article-title>The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators</article-title><source>Can J Cardiol</source><year>1998</year><volume>14</volume><fpage>1349</fpage><lpage>1357</lpage><pub-id pub-id-type="pmid">9854515</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanley</surname><given-names>AJG</given-names></name><name><surname>Harris</surname><given-names>SB</given-names></name><name><surname>Barnie</surname><given-names>A</given-names></name><name><surname>Gittelsohn</surname><given-names>J</given-names></name><name><surname>Wolever</surname><given-names>TMS</given-names></name><name><surname>Logan</surname><given-names>A</given-names></name><name><surname>Zinman</surname><given-names>B</given-names></name></person-group><article-title>The Sandy Lake Health and Diabetes Project: design, methods and lessons learned</article-title><source>Chronic Dis Canada</source><year>1995</year><volume>16</volume><fpage>149</fpage><lpage>156</lpage></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bjerregaard</surname><given-names>P</given-names></name><name><surname>Curtis</surname><given-names>T</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Mulvad</surname><given-names>G</given-names></name><name><surname>Becker</surname><given-names>U</given-names></name><name><surname>Andersen</surname><given-names>S</given-names></name><name><surname>Backer</surname><given-names>V</given-names></name></person-group><article-title>Inuit health in Greenland: a population survey of life style and disease in Greenland and among Inuit living in Denmark</article-title><source>Int J Circumpolar Health</source><year>2003</year><volume>62 Suppl 1</volume><fpage>3</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">14527126</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>KG</given-names></name><name><surname>Zimmet</surname><given-names>P</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name></person-group><article-title>Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation</article-title><source>Diabet Med</source><year>2006</year><volume>23</volume><fpage>469</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">16681555</pub-id><pub-id pub-id-type="doi">10.1111/j.1464-5491.2006.01858.x</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Bell</surname><given-names>JI</given-names></name></person-group><article-title>Association study designs for complex diseases</article-title><source>Nat Rev Genet</source><year>2001</year><volume>2</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">11253062</pub-id><pub-id pub-id-type="doi">10.1038/35052543</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Loos</surname><given-names>RJ</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name></person-group><article-title>Variants in the fat mass- and obesity-associated (FTO) gene are not associated with obesity in a Chinese Han population</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">17959933</pub-id><pub-id pub-id-type="doi">10.2337/db07-1130</pub-id></citation></ref></ref-list></back></article> 